Acumen Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $104.9M | $93.8M | $42.3M | $32.4M | $12.3M | $8.0M |
| SG&A Expense | — | $18.9M | $20.2M | $18.8M | $12.9M | $7.3M | $1.4M |
| Operating Income | — | $-123.8M | $-114.0M | $-61.1M | $-45.2M | $-19.6M | $-7.9M |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | $581.0K | $0 | — | — |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-121.3M | $-102.3M | $-52.4M | $-42.9M | $-100.6M | $-7.3M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-2.00 | $-1.71 | $-1.08 | $-1.06 | $-2.51 | $-8.74 |
| EPS (Diluted) | — | $-2.00 | $-1.71 | $-1.08 | $-1.06 | $-2.51 | $-8.74 |
| Shares Outstanding (Basic) | 72.2M | 60.6M | 60.0M | 48.6M | 40.6M | 40.1M | 838.2K |
| Shares Outstanding (Diluted) | 72.2M | 60.6M | 60.0M | 48.6M | 40.6M | 40.1M | 838.2K |
| Dividends Per Share | — | — | — | — | — | — | — |